Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI) was founded on December 22, 1999 and is headquartered in Irvine, California, with 9 full-time employees (3/31/2018). It is a development stage Medical device and medical equipment company.
Hancock Jaffe Laboratories (HJLI):
Hancock Jaffe Laboratories, Inc. is a development stage medical device company that develops bio-based solutions to improve the quality of life for patients suffering from cardiovascular diseases, peripheral arterial and venous diseases, and end-stage renal disease (ESRD). Every medical device the company is developing is designed to allow vascular and cardiothoracic surgeons to improve existing treatment methods and medical care while providing effective treatment for various patients.
Hancock Jaffe Laboratories is developing and obtaining the following three products approved by the US Food and Drug Administration (FDA):
1. Bioprosthetic Heart Valve-BHV
2. Bioprosthetic Coronary Artery Bypass Graft-CoreoGraft
3. Bioprosthetic Venous Valve-VenoValve
Hancock Jaffe Laboratories previously developed and manufactured ProCol Vascular Bioprosthesis, a hemodialysis vascular access product for ESRD patients, and obtained FDA pre-market approval (FDA pre-market approval), and sold it to LeMaitre Vascular, Inc in March 2016 . (LMAT, Lemaitre Microtubule Medical). According to the agreement with LMAT, Hancock Jaffe Laboratories will continue to manufacture ProCol Vascular Bioprosthesis at its plant in Irvine, California and provide it to LMAT as a transitional service for the acquisition until 2019.
Hancock Jaffe Laboratories (HJLI) investment:
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) submitted its IPO prospectus on 9/7/2017, and finally landed on Nasdaq on 5/31/2018, with a planned issue price of 6.00-8.00 US dollars, the actual issue price is 5 US dollars, 1.5 million shares are issued (initially planned to issue 1.875 million shares), 7.5 million US dollars are raised (initially planned to be 17.25 million US dollars), stock code: HJLI.